Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA approves Bayer’s Stivarga to treat most common liver cancer

Written by: | no-reply@reuters.com | Dated: Thursday, April 27th, 2017

 

The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG’s drug Stivarga to treat liver cancer, the first such approval in nearly a decade.

Stivarga is already approved to treat colorectal cancer in patients who have previously been treated with other therapies. Bayer may now also market it for patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

About 40,710 people will be diagnosed with liver cancers in 2017 and about 28,920 will die of the diseases, according to the National Cancer Institute.

“This is the first time patients with HCC have had an FDA-approved treatment that can be used if their cancer has stopped responding to initial treatment with sorafenib,” Dr. Richard Pazdur, head of the FDA’s cancer division, said in a statement.

Sorafenib, also made by Bayer, is sold under the brand name Nexavar. It was approved initially approved to treat kidney cancer and was approved to treat liver cancer in 2007.

The wholesale price of Stivarga, also known as regorafenib, is $14,881 for one course of treatment. Bayer said it has a number of assistance programs to provide free medication “to eligible Nexavar and Stivarga patients.”

A clinical trial of 573 patients with HCC showed that the median overall survival for patients taking Stivarga was 10.6 months compared with 7.8 months for patients taking a placebo.

 

(This story has been refiled to add dropped word “first” in first paragraph.)

 

(Reporting by Toni Clarke in Washington; Editing by Jonathan Oatis)

 

Reuters source:

http://www.reuters.com/article/us-bayer-cancer-liver-idUSKBN17T2PU

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2017 Focus: Payers, Biotech, HBA WOTY and more!

Subscribe

Ad Right Bottom

Main Navigation